Arthritis News

Thursday, December 11, 2008 One-Shot Synvisc Gets FDA Panel OK
An FDA advisory panel has unanimously recommended approval of Genzyme's Synvisc-One™ single-dose hyalin for knee OA pain...

Wednesday, December 10, 2008 US-Guided Synvisc, Steroids Ease Inoperable Shoulders
Ultrasound-guided hyaluronic acid and steroid offer an alternative for inoperable shoulder impingement syndrome and arthrosynovitis...

Thursday, December 04, 2008 FDA Panel Okays Febuxostat for Gout
A US FDA panel voted 12-0 this week to recommend approval of Takeda Pharmaceutical's febuxostat (Uloric^®), the first new gout drug in 40 years...

Thursday, December 04, 2008 RA Improving Due to Better Management, Not New Drugs
Better monitoring and more aggressive use of old drugs, especially methotrexate, have contributed more to recent improvements in RA outcomes in Spain than the arrival of new drugs such as TNF inhibitors...

Tuesday, November 25, 2008 Who Stays in RA Remission After TNF Blockade Stops?
Patients who start treatment soon after RA symptoms appear, and who have increased functional T-cells, higher levels of interleukin-10, and lower levels of interleukin-12 maintain sustained remission even after stopping TNF-blockers...

Monday, November 24, 2008 New OA Topicals Ease Pain, Protect Stomach
New topical NSAID formulations relieve OA pain without the GI problems associated with oral NSAIDs...

Friday, November 21, 2008 EntreMed Reports Antiangiogenic Role of 2ME2 Demonstrated in RA Models
Preclinical results for 2ME2 (Panzem^® or 2-methoxyestradiol) in rheumatoid arthritis demonstrated that 2ME2 involutes rat collagen-induced arthritis and suppresses synovial VEGF and bFGF gene expression...

Thursday, November 20, 2008 New Therapy Could Transform Arthritis Treatment
Researchers have genetically engineered a modified form of the molecule Foxp3 which helps regulate the body’s immune system and may have important implications for the treatment of rheumatoid arthritis…

Tuesday, November 18, 2008 Phosphagenics’ Transdermal Diclofenac Enters Phase I Clinical Trial
The trial will compare the bioavailability and penetration of the topically applied Voltaren^® gel (1% diclofenac sodium topical gel, Novartis), and Phosphagenics’ TPM/diclofenac (at 1% and 2% diclofenac concentrations) for the targeted delivery of the NSAID diclofenac...

Tuesday, November 18, 2008 Centocor's Golimumab Gives Durable Skin, Joint Relief in Psoriatic Arthritis, ACR Studies Say
More than half of active psoriatic arthritis patients receiving subcutaneous injections of 50 mg or 100 mg of golimumab (CNTO 148) every 4 weeks showed improvements that lasted through 1 year in the joint and skin symptoms...